{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:47:05Z","timestamp":1793119625652,"version":"4.5.0"},"reference-count":19,"publisher":"Japanese Society of Internal Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,6,1]]},"DOI":"10.2169\/internalmedicine.5953-25","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T22:07:27Z","timestamp":1761170847000},"page":"1505-1508","source":"Crossref","is-referenced-by-count":3,"title":["Ulcerative Colitis after Administration of Dupilumab, an Anti-interleukin-4 Receptor Subunit \u03b1 Monoclonal Antibody"],"prefix":"10.2169","volume":"65","author":[{"given":"Hikaru","family":"Mamizu","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Niigata Prefectural Central Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiko","family":"Mamizu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Niigata Prefectural Central Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Niigata Prefectural Central Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Niigata Prefectural Central Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Furukawa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Niigata Prefectural Central Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Niigata Prefectural Central Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Sakai","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Niigata Prefectural Central Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Weinstein IB, Joe AK. Mechanisms of disease: oncogene addiction - a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 3: 448-457, 2006.","DOI":"10.1038\/ncponc0558"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. West NR, Powrie F. Immunotherapy not working? Check your microbiota. Cancer Cell 28: 687-689, 2015.","DOI":"10.1016\/j.ccell.2015.11.010"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. McDermott DF, Atkins MB. PD-1 as potential target in cancer therapy. Cancer Med 2: 662-673, 2013.","DOI":"10.1002\/cam4.106"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Assarzadegan N, Montgomery E, Anders RA. Immune checkpoint inhibitor colitis: the side of the wonder drugs. Virchows Arch 472: 125-133, 2018.","DOI":"10.1007\/s00428-017-2267-z"},{"key":"5","unstructured":"5. Tichy M, Sternbersky J, Palla V. A manifestation of ulcerative colitis during treatment for severe plaue psoriasis with ixekizumab - a report of two cases and review of the literature. Acta Dermatovenerol 29: 232-237, 2021."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Mu X, Fardy J, Reid S, Trahey J. Severe drug-associated colitis with Crohn's features in setting of ixekizumab therapy for chronic plaque psoriasis. BMC Gastroenterol 21: 361, 2021.","DOI":"10.1186\/s12876-021-01936-w"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Philipose J, Ahmed M, Idiculla PS, Mulrooney SM, Gumaste VV. Sever de novo ulcerative colitis followings ixekizumab therapy. Case Rep Gastroenterol 12: 671-621, 2018.","DOI":"10.1159\/000493922"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Chen L, Zou Y, Peng J, et al. Lactobacillus acidophilus suppresses colitis-associated activation of the IL-23\/TH17 axis. J Immunol Res 2015: 909514, 2015.","DOI":"10.1155\/2015\/909514"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Strz\u0119pa A, Szczepanik M. IL-17-expressing cells as a potential therapeutic target for treatment of immunological disorders. Pharmacol Rep 63: 30-44, 2011.","DOI":"10.1016\/S1734-1140(11)70396-6"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Hohenberger M, Cardwell LA, Oussedik E, Feldman SR. Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease. J Dermatolog Treat 29: 13-18, 2018.","DOI":"10.1080\/09546634.2017.1329511"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Moschen AR, Tig H, Raine T. IL-12, IL-23 and IL-23 in IBD: immunobiology and therapeutic targetings. Nat Rev Gastroenterol 16: 185-196, 2019.","DOI":"10.1038\/s41575-018-0084-8"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. O'Connor W Jr, Kamanka M, Booth CJ, et al. A protective function for interleukin 17A in T cell-mediated interstinal inflammation. Nat Immunol 10: 603-609, 2009.","DOI":"10.1038\/ni.1736"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Maxwell JR, Zhang Y, Brown WA, et al. Differential roles for interleukin-23 and interleukin-17 in interstinal immunoregulation. Immunity 43: 739-750, 2015.","DOI":"10.1016\/j.immuni.2015.08.019"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Lee JS, Tato CM, Joyce-Shaikh B, et al. Interleukin-23-independent IL-17 production regulates intestinal epithelial permeability. Immunity 43: 727-738, 2015.","DOI":"10.1016\/j.immuni.2015.09.003"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Harb H, Chatila TA. Mechanisms of dupilumab. Clin Exp Allergy 50: 5-14, 2019.","DOI":"10.1111\/cea.13491"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Guttman-Yassky E, Bissonnette R, Ungar B, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol 143: 155-172, 2019.","DOI":"10.1016\/j.jaci.2018.08.022"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Shimodaira Y, Takahashi S, Iijima K. Anti-IL-4Ralpha monoclonal antibody dupilumab mimics ulcerative colitis: a case report. BMC Gastroenterol 21: 207, 2021.","DOI":"10.1186\/s12876-021-01803-8"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Seishima M, Sakai M, Hachiken H, Furukawa T, Yagi N, Sugie S. Ulcerative colitis during dupilumab therapy in a patient with atopic dermatitis. J Dermatol 50: e420-e421, 2023.","DOI":"10.1111\/1346-8138.16928"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Tursi A, Nenna R. Omalizumab-induced colitis. Dig Liver Dis 53: 1356-1358, 2021.","DOI":"10.1016\/j.dld.2020.08.017"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/11\/65_5953-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T03:28:50Z","timestamp":1780716530000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/11\/65_5953-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5953-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"article-number":"5953-25"}}